Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: A health economic modelling study

Previous PostConceptualisation and validation of a health economic model for osteogenesis imperfecta
Next PostPICO consolidation in European HTA scoping: Examining PICO variations in oncology drugs in the context of the European Joint Clinical Assessment